Effectiveness of impregnated central venous catheters for catheter related blood stream infection: A systematic review

Current Opinion in Infectious Diseases

Volumn 21, Issue 3, 2008, Pages 235-245

  Gilbert, Ruth E ^a   Harden, Melissa ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Central venous catheter; Coating; Impregnation; Infection

Indexed keywords

ANTIBIOTIC AGENT; BENZALKONIUM CHLORIDE; CEFAZOLIN; CHLORHEXIDINE; HEPARIN; MINOCYCLINE; POLYURETHAN; RIFAMPICIN; SILICONE; SILVER; SULFADIAZINE SILVER;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; HUMAN; IN VITRO STUDY; MEDICAL INFORMATION; META ANALYSIS; REVIEW; SEPSIS; SILVER IMPREGNATION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTI-INFECTIVE AGENTS, LOCAL; ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; CHLORHEXIDINE; CROSS INFECTION; EQUIPMENT CONTAMINATION; HEPARIN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SILVER SULFADIAZINE;

EID: 42949099850     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282ffd6e0     Document Type: Review

References (84)

1. Coello R, Charlett A, Ward V, et al. Device-related sources of bacteraemia in English hospitals - opportunities for the prevention of hospital-acquired bacteraemia. J Hosp Infect 2003; 53:46-57.
2. Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use: modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control 2003; 31:1-8.
3. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: potential financial implications. Chest 2003; 124:275-284.
4. Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful? Infect Control Hosp Epidemiol 2000; 21:375-380.
5. Garrouste-Org M, Timsit JF, Tafflet M, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal. Clin Infect Dis 2006; 42:1118-1126.
6. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-1601.
7. Heiselman D. Nosocomial bloodstream infections in the critically ill. JAMA 1994; 272:1819-1820.
8. Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 2007; 7:645-657. A recent overview of new developments to control CRBSIs, including impregnated catheters. Important source for the identification of studies relevant for the current review.
9. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis 2002; 34:1362-1368.
10. Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolaou I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 59:359-369. A recent meta-analysis to examine the efficacy of catheters impregnated with rifampicin in preventing CRBSIs. It includes a summary of findings on selection of specific pathogens. Important source for the identification of studies relevant for the current review.
11. Newman CD. Catheter-related bloodstream infections in the pediatric intensive care unit. Semin Pediatr Infect Dis 2006; 17:20-24.
12. Kline AM. Pediatric catheter-related bloodstream infections: latest strategies to decrease risk. AACN Clin Issues 2005; 16:185-198.
13. de Jonge RC, Polderman KH, Gemke RJ. Central venous catheter use in the pediatric patient: mechanical and infectious complications. Pediatr Crit Care Med 2005; 6:329-339.
14. Herrmann M, Vaudaux PE, Pittet D, et al. Fibronectin, fibrinogen, and laminin act as mediators of adherence of clinical staphylococcal isolates to foreign material. J Infect Dis 1988; 158:693-701.
15. van Rooden CJ, Schippers EF, Guiot HF, et al. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol 2008; 26:428-433.
16. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. The Hospital Infection Control Practices Advisory Committee, Center for Disease Control and Prevention, U.S. Pediatrics 2002; 110:e51.
17. Pratt RJ, Pellowe C, Loveday HP, Robinson N, Smith GW, Barrett S, et al. The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect 2001; 47 (Suppl):S3-S82.
18. Department of Health. Saving Lives: a delivery programme to reduce healthcare associated infections including MRSA. Department of Health: London; 2005.
19. Elliott TS. An update on antimicrobial central venous catheters. J Hosp Infect 2007; 65 (Suppl 2):34-38.
20. Geffers C, Zuschneid I, Eckmanns T, et al. The relationship between methodological trial quality and the effects of impregnated central venous catheters. Intensive Care Med 2003; 29:403-409.
21. Niël-Weise BS, Stijnen T, van den Broek PJ. Antiinfective-treated central venous catheters: a systematic review of randomized controlled trials. Intensive Care Med 2007; 33:2058-2068. A recent systematic review that includes additional randomised trials of antiinfective-treated CVCs on CRBSI published since Veenstra review in 1999 [34].
22. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000; 26:967-972.
23. Brun-Buisson C, Doyon F, Sollet JP, et al. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intensive Care Med 2004; 30:837-843.
24. Bong JJ, Kite P, Wilco MH, McMahon MJ. Prevention of catheter related bloodstream infection by silver iontophoretic central venous catheters: a randomised controlled trial. J Clin Pathol 2003; 56:731-735.
25. Eggimann P. Prevention of intravascular catheter infection. Curr Opin Infect Dis 2007; 20:360-369.
26. Paglialonga F, Esposito S, Edefonti A, Principi N. Catheter-related infections in children treated with hemodialysis. Pediatr Nephrol 2004; 19:1324-1333.
27. Long DA, Coulthard MG. Effect of heparin-bonded central venous catheters on the incidence of catheter-related thrombosis and infection in children and adults. Anaesth Intensive Care 2006; 34:481-484.
28. Swann D. Do antimicrobial central venous catheters prevent catheter-related blood stream infection in intensive care patients. EBM Reviews Scottish Intensive Care Society EBM Group; 2005. http://www.sicsebm.org.uk/ CVCrBSI/Catheter/CVCrBSI.type.summary.htm.
29. Barrington KJ. Umbilical artery catheters in the newborn: effects of catheter materials. Cochrane Database Syst Rev 2000:CD000949.
30. Marin MG, Lee JC, Skurnick JH. Prevention of nosocomial bloodstream infections: effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. Crit Care Med 2000; 28:3332-3338.
31. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132:391-402.
32. Randolph AG, Cook DJ, Gonzales CA, Andrew M. Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest 1998; 113:165-171.
33. Shah PS, Shah N. Heparin-bonded catheters for prolonging the patency of central venous catheters in children. Cochrane Database Syst Rev 2007: CD005983.
34. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related blood-stream infection. JAMA 1999; 282:554-560.
35. Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999; 281:261-267.
36. Appelgren P, Ransjo U, Bindslev L. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial. Crit Care Med 1996; 24:1482-1489.
37. Abdelkefi A, Achour W, Ben OT, et al. Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. J Support Oncol 2007; 5:273-278.
38. Ciresi DL, Albrecht RM, Volkers PA, et al. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am Surg 1996; 62:641-646.
39. Pemberton LB, Ross V, Cuddy P, et al. No difference in catheter sepsis between standard and antiseptic central venous catheters: a prospective randomized trial. Arch Surg 1996; 131:986-989.
40. George SJ, Vuddamalay P, Boscoe MJ. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur J Anaesthesiol 1997; 14:428-431.
41. Logghe C, Van O, Hoore W, et al. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J Hosp Infect 1997; 37:145-156.
42. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. . . including commentary by Pearson ML and Abrutyn E. Ann Inter Med 1997; 127:257-266.
43. Tennenberg S, Lieser M, McCurdy B, et al. A prospective randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch Surg 1997; 132:1348-1351.
44. Heard SO, Wagle M, Vijayakumar E, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Inter Med 1998; 158:81-87.
45. Collin GR. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter. Chest 1999; 115:1632-1640.
46. Hannan M, Juste RN, Umasanker S, et al. Antiseptic-bonded central venous catheters and bacterial colonisation. Anaesthesia 1999; 54:868-872.
47. Marik PE, Abraham G, Careau P, et al. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med 1999; 27:1128-1131.
48. Sheng WH, Ko WJ, Wang JT, et al. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diag Microbiol Infect Dis 2000; 38:1-5.
49. Dunser MW, Mayr AJ, Hinterberger G, et al. Central venous catheter colonization in critically ill patients: a prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesth Analg 2005; 101:1778-1784.
50. Jaeger K, Zenz S, Juttner B, et al. Reduction of catheter-related infections in neutropenic patients: a prospective controlled randomized trial using a chlorhexidine and silver sulfadiazine-impregnated central venous catheter. Ann Hematol 2005; 84:258-262.
51. Ostendorf T, Meinhold A, Harter C, et al. Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients - a double-blind, randomised, prospective, controlled trial. Support Care Cancer 2005; 13: 993-1000.
52. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 2005; 143:570-580.
53. Osma S, Kahveci SF, Kaya FN, et al. Efficacy of antiseptic-impregnated catheters on catheter colonization and catheter-related bloodstream infections in patients in an intensive care unit. J Hosp Infect 2006; 62:156-162.
54. Ramos G, Bolgiani A, Patifno O, et al. Antiseptic-impregnated central venous catheters: their evaluation in burn patients. Ann Burns Fire Disasters 2006; XIX:63-67.
55. Kamal GD, Pfaller MA, Rempe LE, Jebson PJR. Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. J Am Med Assoc 1991; 265:2364-2368.
56. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. Ann Inter Med 1997; 127:267-274.
57. Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 2004; 22:3163-3171.
58. Leon C, Ruiz-Santana S, Rello J, et al. Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Med 2004; 30:1891-1899.
59. Yücel N, Lefering R, Maegele M, et al. Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial. J Antimicrob Chemother 2004; 54:1109-1115.
60. Darouiche RO, Berger DH, Khardori N, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Ann Surg 2005; 242:193-200.
61. Harter C, Salwender HJ, Bach A, et al. Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters. Cancer 2002; 94:245-251.
62. Ranucci M, Isgro G, Giomarelli PP, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med 2003; 31:52-59.
63. Corral L, Nolla-Salas M, Ibanez-Nolla J, et al. A prospective, randomized study in critically ill patients using the Oligon Vantex catheter. J Hosp Infect 2003; 55:212-219.
64. Moretti EW, Ofstead CL, Kristy RM, Wetzler HP. Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia. J Hosp Infect 2005; 61:139-145.
65. Kalfon P, de Vaumas C, Samba D, et al. Comparison of silver-impregnated with standard multilumen central venous catheters in critically ill patients. Crit Care Med 2007; 35:1032-1039.
66. Fraenkel D, Rickard C, Thomas P, et al. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Crit Care Med 2006; 34:668-675.
67. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobialimpregnated central venous catheters Catheter Study Group. N Engl J Med 1999; 340:1-8.
68. Carrasco MN, Bueno A, De L, et al. Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. Intensive Care Med 2004; 30:633-638.
69. Bach A. A randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch Surg 1998; 133:1022.
70. Bennegard K, Curelaru I, Gustavsson B, et al. Material thrombogenicity in central venous catheterization. I: A comparison between uncoated and heparin-coated, long antebrachial, polyethylene catheters. Acta Anaesthesiol Scand 1982; 26:112-120.
71. Borschel DM, Chenoweth CE, Kaufman SR, et al. Are antiseptic-coated central venous catheters effective in a real-world setting? Am J Infect Control 2006; 34:388-393.
72. Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. J Pediatr 1995; 126:50-54.
73. Schuerer DJ, Zack JE, Thomas J, et al. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial. Surg Infect (Larchmt) 2007; 8:445-454.
74. Trazzera S, Stern F, Rakesh B, et al. Examination of antimicrobial coated central venous catheters in patients at high risk for catheter related infections in a medical intensive care unit and leukemia/bone marrow transplant unit [abstract]. Crit Care Med 1995; 23:A152.
75. Chatzinikolaou I, Finkel K, Hanna H, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med 2003; 115:352-357.
76. Timsit JF, Farkas JC, Boyer JM. Central vein catheter-related thrombosis in intensive care patients: incidence, risk factors, and relationship with catheter-related sepsis. Chest 1998; 114:207-213.
77. Cheung J, O'Leary JJ. Allergic reaction to chlorhexidine in an anaesthetised patient. Anaesth Intensive Care 1985; 13:429-430.
78. Ohtoshi T, Yamauchi N, Tadokoro K, et al. IgE antibody-mediated shock reaction caused by topical application of chlorhexidine. Clin Allergy 1986; 16:155-161.
79. Okano M, Nomura M, Hata S, et al. Anaphylactic symptoms due to chlorhexidine gluconate. Arch Dermatol 1989; 125:50-52.
80. Burlington B. FDA Public Health Notice: potential hypersensitivity reactions to chlorhexidine-impregnated medical devices. FDA, US Food and Drug Administration; 1998 [cited 2008]. http://www.fda.gov/cdrh/chlorhex.html.
81. Tattawasart U, Maillard JY, Furr JR, Russell AD. Development of resistance to chlorhexidine diacetate and cetylpyridinium chloride in Pseudomonas stutzeri and changes in antibiotic susceptibility. J Hosp Infect 1999; 42:219-229.
82. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol 2001; 22:640-646.
83. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358:135-138.
84. Saint S, Veenstra DL, Sullivan SD. The use of meta-analysis in cost-effectiveness analysis. Issues and recommendations. Pharmacoeconomics 1999; 15:1-8.